The Inhibition of Acetylcholinesterase by Dantrolene and Ondansetron

Abstract

Purpose:

A virtual screening study has suggested that the skeletal muscle relaxant, dantrolene, and the antiemetic drug, ondansetron, may act as inhibitors of the enzyme acetylcholinesterase (AChE). Based on this proposal, the current study examines the AChE inhibitory properties of these drugs.

Methods and Findings:

Using AChE from human erythrocytes as enzyme source, it is shown that dantrolene and ondansetron inhibit AChE with IC₅₀ values of 12.8 µM and 37.1 µM, respectively. For comparison, the reference AChE inhibitors, tacrine and ranitidine, exhibit IC₅₀ values of 0.144 µM and 3.37 µM, respectively. By measuring the recoveries of enzyme activities after dilution of enzyme-inhibitor mixtures, it is further shown that dantrolene and ondansetron act as reversible AChE inhibitors.

Conclusions:

By considering the typical plasma concentrations of dantrolene and ondansetron in humans at therapeutic doses, the pharmacological relevance of the AChE inhibitory potencies of these drugs is discussed. At typical plasma concentrations, ondansetron is unlikely to inhibit AChE under physiological conditions. The inhibition of AChE by ondansetron is therefore not of clinical relevance in humans. In contrast, after intravenous administration of dantrolene to humans, the typical plasma concentrations reached are similar to the recorded IC₅₀ value for the inhibition of AChE, and dantrolene may thus produce pharmacological significant inhibition of AChE. Further investigation is necessary to clarify the pharmacological relevance of the AChE inhibitory effect of dantrolene.

Key words

acetylcholinesterase - dantrolene - ondansetron - inhibition - ondansetron

• References

• 1 Silman I, Sussman JL.. Acetylcholinesterase: ‘classical’ and ‘non-classical’ functions and pharmacology. Curr Opin Pharmacol 2005; 5: 293-302
• 2 Dvir H, Silman I, Harel M et al. Acetylcholinesterase: from 3D structure to function. Chem Biol Interact 2010; 187: 10-22
• 3 Pohanka M.. Cholinesterases, a target of pharmacology and toxicology. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2011; 155: 219-229
• 4 Holzgrabe U, Kapková P, Alptüzün V et al. Targeting acetylcholinesterase to treat neurodegeneration. Expert Opin Ther Targets 2007; 11: 161-179
• 5 Giacobini E. Cholinesterases: new roles in brain function and in Alzheimer’s disease. Neurochem Res 2003; 28: 515-522
• 6 Nordberg A. Mechanisms behind the neuroprotective actions of cholinesterase inhibitors in Alzheimer disease. Alzheimer Dis Assoc Disord 2006; 20: S12-S18
• 7 Inestrosa NC, Alvarez A, Pérez CA et al. Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer’s fibrils: possible role of the peripheral site of the enzyme. Neuron 1996; 16: 881-891
• 8 De Ferrari GV, Canales MA, Shin I et al. A structural motif of acetylcholinesterase that promotes amyloid beta-peptide fibril formation. Biochemistry 2001; 40: 10447-10457
• 9 Medina-Franco JL, Giulianotti MA, Welmaker GS et al. Shifting from the single to the multitarget paradigm in drug discovery. Drug Discov Today 2013; 18: 495-501
• 10 Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov 2004; 3: 673-683
• 11 Krause T, Gerbershagen MU, Fiege M et al. Dantrolene: a review of its pharmacology, therapeutic use and new developments. Anaesthesia 2004; 59: 364-373
• 12 Ye JH, Ponnudurai R, Schaefer R. Ondansetron: a selective 5-HT(3) receptor antagonist and its applications in CNS-related disorders. CNS Drug Rev 2001; 7: 199-213
• 13 Ellman GL, Courtney KD, Andres V et al. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961; 7: 88-95
• 14 Marco JL, de los Ríos C, Carreiras MC et al. Synthesis and acetylcholinesterase/butyrylcholinesterase inhibition activity of new tacrine-like analogues. Bioorg Med Chem 2001; 9: 727-732
• 15 Laine-Cessac P, Turcant A, Premel-Cabic A et al. Inhibition of cholinesterases by histamine 2 receptor antagonist drugs. Res Commun Chem Pathol Pharmacol 1993; 79: 185-193
• 16 Kraut D, Goff H, Pai RK et al. Inactivation studies of acetylcholinesterase with phenylmethylsulfonyl fluoride. Mol Pharmacol 2000; 57: 1243-1248
• 17 Millard CB, Kryger G, Ordentlich A et al. Crystal structures of aged phosphonylated acetylcholinesterase: nerve agent reaction products at the atomic level. Biochemistry 1999; 38: 7032-7039
• 18 Wilson IB, Quan C. Acetylcholinesterase studies on molecular complementariness. Arch Biochem Biophys 1958; 73: 131-143
• 19 Harel M, Schalk I, Ehret-Sabatier L et al. Quaternary ligand binding to aromatic residues in the active-site gorge of acetylcholinesterase. Proc Natl Acad Sci USA 1993; 90: 9031-9035
• 20 Kryger G, Silman I, Sussman JL. Structure of acetylcholinesterase complexed with E2020 (Aricept): implications for the design of new anti-Alzheimer drugs. Structure 1999; 7: 297-307
• 21 Strum WB. Ranitidine. J Amer Med Assoc 1983; 250: 1894-1896
• 22 de Wit R, Beijnen JH, van Tellingen O et al. Pharmacokinetic profile and clinical efficacy of a once-daily ondansetron suppository in cyclophosphamide-induced emesis: a double blind comparative study with ondansetron tablets. Br J Cancer 1996; 74: 323-326
• 23 Ashforth EI, Palmer JL, Bye A et al. The pharmacokinetics of ondansetron after intravenous injection in healthy volunteers phenotyped as poor or extensive metabolisers of debrisoquine. Br J Clin Pharmacol 1994; 37: 389-391
• 24 Petzer A, Harvey BH, Wegener G et al. Azure B, a metabolite of methylene blue, is a high-potency, reversible inhibitor of monoamine oxidase. Toxicol Appl Pharmacol 2012; 258: 403-409
• 25 Capacio BR, Byers CE, Anderson DR et al. The effect of ondansetron on pyridostigmine-induced blood acetylcholinesterase inhibition in the guinea pig. Drug Chem Toxicol 1996; 19: 1-19
• 26 Kirkby DL, Jones DN, Barnes JC et al. Effects of anticholinesterase drugs tacrine and E2020, the 5-HT(3) antagonist ondansetron, and the H(3) antagonist thioperamide, in models of cognition and cholinergic function. Behav Pharmacol 1996; 7: 513-525
• 27 Flewellen EH, Nelson TE, Jones WP et al. Dantrolene dose response in awake man: implications for management of malignant hyperthermia. Anesthesiology 1983; 59: 275-280
• 28 Kodaira H, Kusuhara H, Fujita T et al. Quantitative evaluation of the impact of active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier on the predictability of the unbound concentrations of drugs in the brain using cerebrospinal fluid concentration as a surrogate. J Pharmacol Exp Ther 2011; 339: 935-944
• 29 Chakroborty S, Briggs C, Miller MB et al. Stabilizing ER Ca²⁺ channel function as an early preventative strategy for Alzheimer’s disease. PLoS One 2012; 7: e52056